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Abstract
Remyelination following CNS demyelination restores rapid signal propagation and protects axons; however, its efficiency 
declines with increasing age. Both intrinsic changes in the oligodendrocyte progenitor cell population and extrinsic factors 
in the lesion microenvironment of older subjects contribute to this decline. Microglia and monocyte-derived macrophages 
are critical for successful remyelination, releasing growth factors and clearing inhibitory myelin debris. Several studies have 
implicated delayed recruitment of macrophages/microglia into lesions as a key contributor to the decline in remyelination 
observed in older subjects. Here we show that the decreased expression of the scavenger receptor CD36 of aging mouse 
microglia and human microglia in culture underlies their reduced phagocytic activity. Overexpression of CD36 in cultured 
microglia rescues the deficit in phagocytosis of myelin debris. By screening for clinically approved agents that stimulate mac-
rophages/microglia, we have found that niacin (vitamin B3) upregulates CD36 expression and enhances myelin phagocytosis 
by microglia in culture. This increase in myelin phagocytosis is mediated through the niacin receptor (hydroxycarboxylic 
acid receptor 2). Genetic fate mapping and multiphoton live imaging show that systemic treatment of 9–12-month-old demy-
elinated mice with therapeutically relevant doses of niacin promotes myelin debris clearance in lesions by both peripherally 
derived macrophages and microglia. This is accompanied by enhancement of oligodendrocyte progenitor cell numbers and 
by improved remyelination in the treated mice. Niacin represents a safe and translationally amenable regenerative therapy 
for chronic demyelinating diseases such as multiple sclerosis.
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Introduction
The loss of the myelin sheath has significant consequences 
for axonal health and conduction velocity [17, 29, 42]. 
Although demyelinated axons have mechanisms to compen-
sate for the loss of the insulative myelin sheath, these axons 
are ultimately more prone to degeneration. Remyelination is 
an endogenous process that restores rapid signal propagation 
and protects axons, but the process is usually incomplete 
and becomes inefficient with advanced age in rodents [47]. 
Both intrinsic changes in the oligodendrocyte progenitor cell 
(OPC) population as well as the extrinsic lesion microenvi-
ronment are thought to underlie the decreased remyelina-
tion efficiency in older animals after demyelination, likely 
accelerating their rate of axonal loss [5, 12, 35, 41, 45, 46].
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Innate immune cells such as resident microglia and infil-
trating macrophages are critical components to successful 
remyelination, as they release important growth factors and 
clear inhibitory myelin debris [5, 23, 24, 30, 41]. Several 
studies have associated the reduced remyelination of older 
animals with a dysregulated innate immune response that 
manifests as delayed recruitment of macrophages/microglia 
into lesions [53], and their deficient motility and phagocy-
tosis of myelin debris within lesions [5, 34, 39, 41, 43]. 
Heterochronic parabiosis of older demyelinated mice paired 
with young mice resulted in infiltration of young mac-
rophages and enhanced remyelination [41]. These results of 
parabiotic young macrophages altering the inhibitory lesion 
microenvironment of older mice suggest that pharmacologi-
cal stimulation is a practical means to rejuvenate deficient 
macrophages/microglia to promote remyelination in older 
individuals.
We sought to identify a clinically approved medication to 
stimulate the beneficial properties of macrophages/micro-
glia for remyelination in subjects with increasing age. By 
screening a library of 1040 mainly generic medications for 
the capacity to activate macrophages/microglia, we dis-
covered niacin, or vitamin B3, to enhance macrophage/
microglia cytokine secretion and phagocytosis in vitro. The 
screening results led us to investigate whether systemic 
niacin therapy in the lysolecithin model of demyelination 
could alter lesional macrophages/microglia to foster myelin 
repair in 9–12-month-old (henceforth referred to as mid-
dle-aged) mice. Our collective results highlight the deficits 
in debris removal in lesions of middle-aged compared to 
young 2–3-month-old animals, and they identify a novel, 
clinically tolerable medication that restores critical func-
tions of macrophages/microglia to promote aging-deficient 
remyelination.
Materials and methods
Mice
All in vivo mouse experiments were conducted with ethical 
approval from the Animal Care Committee at the University 
of Calgary under regulations stated by the Canadian Council 
of Animal Care. Female C57Bl/6 mice from Charles River 
were used for lysolecithin demyelination at 2–3 months 
or 9–12 months of age. For the multiphoton live imaging 
experiments, heterozygous  CX3CR1GFP/+ mice [18] were 
crossed with  Thy1YFP+ mice [11] to produce double trans-
genic mice enabling the visualization of both macrophages/
microglia and axons [39]. To determine whether niacin 
was signaling through the niacin receptor on macrophages, 
 Hcar2−/− mice [49] were used. To discriminate between 
microglia and bone marrow-derived monocytes, male and 
female  CX3CR1CreER:Rosa26Tdt (also referred to as Ai9) 
mice were employed [36].
Lysolecithin demyelination
All surgeries were started in the morning and mice were 
anesthetized with an intraperitoneal injection of ketamine 
(100  mg/kg) and xylazine (10  mg/kg). Buprenorphine 
(0.05 mg/kg) was injected subcutaneously immediately 
prior to surgery and 12–16 h post-surgery as an analgesic. 
The tissue between T3 and T4 was removed with spring 
scissors, exposing the dorsal spinal cord, after which the 
dura was cleared with a 30-gauge metal needle. For all his-
tology experiments and electron microscopy experiments, 
focal demyelination was produced by injection of the lipid-
disrupting detergent lysolecithin (L1381, Sigma, lysophos-
phatidylcholine, LPC) into the ventrolateral funiculus as 
described previously [20]. For multiphoton live imaging 
experiments, LPC was injected into the dorsal column as 
performed before [39]. For experiments in which demyeli-
nated mice were treated with niacin, mice were administered 
with either saline vehicle or niacin (100 mg/kg) intraperito-
neally once a day commencing 1 day after surgery.
Ex vivo multiphoton live imaging
Ex vivo multiphoton live imaging was performed as 
described previously [39] using a Nikon A1R multiphoton 
microscope. A 25X water-immersion apochromatic lens with 
a 1.1 NA was used along with a spectral detector in which 
emission spectra ranging from 490 to 650 nm was collected 
at 10 nm intervals. Images were acquired as Z-stacks with an 
optical thickness of ≈ 1.5 μm per slice with x–y dimensions 
of 200 μm by 200 μm centered over the lesion. Z-stacks were 
approximately 30 μm in depth and were captured over the 
same location every 15 min over 2–3 h. After acquisition, 
images were spectrally unmixed using NIS-Elements. To 
obtain four-dimensional morphological and dynamic data 
of  CX3CR1GFP/+ cells, unmixed time series were imported 
into Imaris for three-dimensional surface reconstruction. 
ImarisTrack was used to obtain features of motility for 
 CX3CR1GFP/+ cells and ImarisColoc was used to quantify 
the percentage of Nile Red phagocytosis.
Histology and immunofluorescence
Mice were anesthetized and then transcardially perfused 
with 20  mL of cold phosphate-buffered saline (PBS) 
and cold 4% phosphate-buffered paraformaldehyde 
(PFA). After dissecting the spinal cord, a 1 cm segment 
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encompassing the T3–T4 thoracic spinal cord was isolated. 
This segment was subsequently post-fixed in 4% PFA for 
24 h at 4 °C, after which the samples were cryoprotected 
in 30% sucrose for 3 nights at 4 °C. These samples were 
then frozen in cryomolds with optimal cutting tempera-
ture (OCT; 25608-930, VWR) in a chamber containing 
2-methylbutane (M32631, Sigma) and dry ice. Coronal 
sections of 20 μm thickness were stained with eriochrome 
cyanine R (32752, Sigma) and 1% neutral red (N-129-25, 
Fisher Scientific) as previously described [21] to identify 
the lesion epicenter.
For immunofluorescence staining, frozen slides con-
taining sections immediately adjacent to the lesion epi-
centers were thawed, and sections were delipidated in 
graded ethanol solutions when staining for MBP. Slides 
after blocking were incubated overnight with primary anti-
bodies: rabbit polyclonal anti-Olig2 antibody (EMD Mil-
lipore, AB9610; 1:200) and goat polyclonal anti-PDGFRα 
antibody (R&D Systems, AF1062; 1:100) for OPCs; rat 
monoclonal anti-MBP antibody (Abcam, ab7349; 1:100) 
or rabbit polyclonal anti-MBP antibody (Abcam, ab40390; 
1:1000) for myelin; rat polyclonal anti-CD45 antibody 
(BD Pharmingen, 550539; 1:100) and rabbit polyclonal 
anti-Iba1 antibody (Wako, 019-19741; 1:500) for mac-
rophages/microglia; rabbit polyclonal anti-CD36 anti-
body (Novus Biologicals, NB400-144; 1:100); and rabbit 
polyclonal anti-IL-1β antibody (Rockland, 210-401-319; 
1:50). The corresponding fluorophore-conjugated second-
ary antibodies (1:400) were then added with nuclear yel-
low (1:1000). Slides were coverslipped and fluorescent 
images were captured on a Nikon C1si spectral confocal 
microscope; brightness and contrast was adjusted using 
ImageJ.
To histologically examine phagocytosed lipids, tis-
sue sections were stained with Oil Red O as previously 
described [24, 41]. ImageJ was used to threshold the Oil 
Red O images, allowing the degree of punctate Oil Red O 
to be analyzed.
Flow cytometry
We conducted flow cytometry to investigate the inflam-
matory state of circulating blood monocytes as previously 
described [2]. The primary antibodies used were CD45-
PerCP (BD Pharmingen; Clone 30-F11), CD11b-FITC (BD 
Pharmingen; Clone M1/70), Ly6G-APC-Cy7 (BD Pharmin-
gen; Clone 1A8), and Ly6C-V450 (BD Horizon; Clone 
AL-21). Data were acquired on a BD LSRII flow cytometer. 
Unstained samples, appropriate isotype controls, as well as 
single-stain controls were used for compensation and gating. 
Data were analyzed using FlowJo software.
Transmission electron microscopy
To assess remyelination ultrastructurally, mice were anes-
thetized and transcardially perfused with 20 mL of ice-
cold PBS followed by 20 mL of 2.5% glutaraldehyde in 
4% phosphate-buffered paraformaldehyde. The spinal cord 
was carefully dissected and a 3 mm segment surround-
ing the lesion was isolated. The lesion segments were 
then post-fixed overnight in the same fixative at 4 °C. 
The lesion segments were rinsed three times with 0.1 M 
cacodylate. After rinsing, the segments were fixed with 
1% osmium tetroxide in 0.1 M cacodylate for 1 h at room 
temperature. The segments were then dehydrated in graded 
ethanols and embedded in Epon resin for sectioning as 
semi-thins on a Leica EM UC6 ultramicrotome. The semi-
thins were stained with 1% toluidine blue and 2% borax 
to determine whether lesions are present. Once lesions 
were identified, segments were further processed as 70 nm 
ultra-thin sections and then contrasted with lead citrate for 
examination under a Hitachi 7650 transmission electron 
microscope. Images were captured at 1000× magnifica-
tion, ensuring that the entire lesion was captured. Images 
were blinded and then randomly selected for analysis. 
ImageTrak was used to measure the g ratio (diameter of 
the axon divided by the diameter of the axon and myelin 
sheath) of individual axons within the lesion core until 300 
axons per lesion were measured.
Laser capture microdissection and RNA 
sequencing
Young (6 weeks old) and middle-aged (8 months old) 
mice were perfused with RNase-free PBS and spinal cords 
from naïve and injured (72 h) mice were isolated, placed 
in optimum cutting temperature compound (Tissue-Tek), 
and snap frozen in a mixture of dry ice and isopentane. 
20 µm cryosections were collected on nuclease free PEN-
membrane slides (Zeiss), fixed in 70% ethanol (vol/vol), 
stained with 1% cresyl violet (wt/vol), and dehydrated with 
70% and 100% ethanol. Laser capture microdissection was 
performed on the PALM MicroBeam. Total RNA was iso-
lated using RNeasy Mini Kit (Qiagen) from dissected tis-
sue. Qubit RNA HS assay kit (Thermo Fisher) was then 
used to determine RNA concentrations and Agilent 2200 
TapeStation to assess RNA quality. RNA samples with 
RIN > 8 were used for sequencing.
RNA was amplified at the library building step using 
the REPLI-g protocol and sequencing was performed on 
an Illumina NextSeq500 platform. FastQC (version 0.11.4) 
was used to determine the quality of sequencing reads 
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before being mapped to the genome using TopHat (version 
2.0.10) with bowtie (version 1.1.2) as an internal aligner. 
Raw read counts were acquired with featureCounts and 
read into R (version 3.3.2). Pairwise comparisons were 
conducted using the DESeq2 package from Bioconductor. 
The data reported in this paper have been deposited in the 
Gene Expression Omnibus, https ://www.ncbi.nlm.nih.gov/
geo/query /acc.cgi (accession no. GSE 129000).
Isolation of mouse bone marrow‑derived 
macrophages, microglia and OPCs
Mouse bone marrow-derived macrophages (BMDM) were 
isolated as previously described [10]. For microglia, brain 
tissue was diced into small pieces and incubated at 37 °C 
for 30 min in a dissociation solution, consisting of 34 U/
mL papain and 20 μg/mL DNAse in HALF (Hibernate-A 
equivalent, made in house). After this, tissue was tritu-
rated with a fire-polished glass pipette, passed through a 
70 μm cell strainer (Millipore) and centrifuged for 20 min at 
800 g in 22.5% Percoll. The pellet, containing single cells, 
was labeled with magnetic bead-conjugated antibodies 
for CD11b and CD11b+ microglia were eluted by MACS 
according to the manufacturer’s instructions. Microglia 
were cultured at  104 cells per well of a poly-d-lysine-coated 
96-well microplate, in DMEM/F12 supplemented with 10% 
fetal bovine serum (FBS), 2% B27, 500 μM N-acetylcysteine 
and 1% penicillin–streptomycin. After 48 h, medium was 
changed to macrophage serum-free medium (Thermo Fisher 
Scientific). Finally, OPCs were isolated from CD-1 pups 
aged P0–P2 as previously described [20].
Biopsy of human brain tissue
Human brain tissue was obtained with informed consent 
under protocol 16/LO/2168 approved by the NHS Health 
Research Authority. Adult brain tissue biopsies were taken 
from the site of neurosurgery resection for the original 
clinical indication. Tissue was transferred to hibernate-A 
low fluorescence (HALF; in house made) supplemented 
with 1 × SOS, 2% GlutaMAX (Life Technologies), 1% P/S 
(Sigma), 0.1% BSA, insulin (4 μg/mL), pyruvate (220 μg/
mL) and DNase 1 Type IV (40 μg/mL) on ice and trans-
ported to a CL 2 laboratory.
Myelin isolation
Whole brains were removed from three young adult C57Bl/6 
mice and myelin was isolated using a discontinuous sucrose 
gradient. Brains were homogenized in 20 mL 0.32 M sucrose 
and 10 mL of homogenate was layered between 18.5 mL 
0.85 M sucrose and 8.5 mL 0.32 M sucrose and ultracentri-
fuged at 75,000g for 20 min with no brake. The interface was 
collected, homogenized in 35 mL distilled water and then 
ultracentrifuged at 75,000g for a further 15 min. Supernatant 
was aspirated, the pellet re-suspended in 35 mL distilled 
water, then ultracentrifuged at 12,000g for 10 min. The pel-
let was re-suspended in 10 mL 0.32 M sucrose, layered over 
20 mL 0.85 M sucrose in a clean tube and then ultracentri-
fuged at 75,000g for 30 min. Finally, the interface was col-
lected and centrifuged at 16,000g for 15 min to concentrate 
the myelin, which was stored at − 80 °C.
Microglia stimulation assays
Cells were stimulated in macrophage serum-free medium 
(Thermo Fisher Scientific) with 2% B27, 500 μM N-acetyl-
cysteine, 1% penicillin–streptomycin and 10 ng/mL mac-
rophage colony-stimulating factor (M-CSF). Latex beads or 
myelin were used at concentrations of 0.1 μL/mL and 10 μg/
mL, respectively. Sulfo-N-succinimidyl oleate (SSO) was 
used to inhibit CD36 activity at a range of concentrations 
up to 200 μg/mL.
Microglia RNA extraction, quality 
assessment, and RNA sequencing
Total RNA from primary microglia was extracted with the 
Qiagen AllPrep DNA/RNA micro kit (80284). The integrity 
and quantity of the total RNA were assessed using an Agi-
lent Technologies Bioanalyser RNA Pico kit (5067-1513). 
Between 0.3 and 10 ng of total RNA was used as input for 
the RNA-seq library preparation.
Genes for which the count value was equal to zero in all 
samples were filtered out and 41,677 genes remained for 
statistical analyses. Analysis of deviance (ANODEV) was 
performed by employing DEseq2 and a generalized linear 
model (GLM) design (= ag + ac + ag:ac) where we consider 
the effect of aging (ag), microglia activation (ac), and the 
interaction of these two factors (ag:ac). The likelihood ratio 
test (LRT) p values (for the effect of aging and the effect of 
microglia activation) were determined and adjusted to cor-
rect for multiple testing using FDR (Benjamini–Hochberg). 
Expression levels of genes for which FDR < 0.05 (for both 
the effect of aging and the effect of microglia activation) 
were considered differentially expressed and 1714 genes 
were identified. They are collectively named DAA (gene 
set differentially expressed as an effect of microglia activa-
tion and aging). For specific contrast analysis between two 
groups, Wald test was performed and p values were adjusted 
using FDR.
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Microglia mRNA pulldown, reverse 
transcription, and template switching
RNA samples were diluted to 25 µL with 10 mM Tris–HCl 
(pH 8.0) before adding 25 µL of 2 × lysis binding buffer. 
20 µL of oligo dT beads were placed into each well of a 
96-well plate and placed on the magnet. Supernatant was 
discarded and washed once with 100 µL lysis/binding buffer. 
The pelleted bead was re-suspended in 50 µL RNA and incu-
bated at room temperature for 15 min. Samples were placed 
on the magnet with supernatant discarded, and eluted in 
50 µL. Samples were washed again and eluted in 9.5 µL 
elution buffer by incubating at 75 °C for 2 min. Samples 
were immediately transferred to the magnet and 7 µL were 
transferred to a new plate and kept on ice. Samples were 
then incubated at 72 °C for 3 min and rapidly chilled on ice. 
Thereafter, samples were added to 5 µL 5 × SmartScribe FS 
Buffer (Takara Clontech 072915), 0.63 µL SUPERase Inhib-
itor (Thermo Fisher AM2696), 1.25 µL 0.1 M dithiothreitol, 
5 µL 5 M betaine, 0.15 µL 1 M  MgCl2, 0.38 µL 100 µM 
TSO, and 1.25  µL SMARTScribe reverse transcriptase 
(Takara Clontech 639538). Samples were then incubated for 
ten cycles before 25 µL NFW (total 50 µL) was added to per-
form 0.8:1 Ampure XP clean-up on Zephyr. Samples were 
then added to 13 µL of PCR master mix comprising 12.5 µL 
2 × KAPA HiFi HS (KapaBiosystems KK2601) and 0.5 µL 
10 µM ISPCR primer. The samples were run for 11 cycles 
with an annealing temperature of 67 °C for 15 s. Samples 
were added to 25 µL NFW (total 50 µL) for clean up with 
0.8:1 Ampure XP, eluting in 20 µL 10 mM Tris–HCl (pH 
8.0). Samples were read on a BMG Pherastar.
Nextera Library preparation and PCR
Four nanograms of cDNA was diluted into a total volume 
of 9.5 µL with 10 mM Tris–HCl (pH 8.0), on ice, prior to 
tagmentation. 5.5 µL of tagmentation mastermix (Illumina 
FC-121-1030) was added and briefly vortexed for 5 s. Sam-
ples were incubated at 55 °C for 5 min, and then cooled to 
15 °C. To this, 2.5 µL of Tn5 release buffer was added and 
incubated at room temperature for 10 min. 35 µL of 10 mM 
Tris–HCl (pH 8.0) was added and 1.8:1 Ampure XP clean-
up was performed on Pre-PCR Zephyr. Samples were eluted 
in 10 µL of Tris–HCl (pH 8.0). 7 µL of tagmented cDNA 
(allows for dead volume) was removed for PCR. The primers 
were Oligo-dT30 VN (with RNase-free HPLC purification):
5′ AAG CAG TGG TAT CAA CGC AGA GTA CTT TTT 
TTT TTT TTT TTT TTT TTT TTT TTT TVN 3′
Template-switching LNA oligo (TSO): 5′ AAG CAG 
TGG TAT CAA CGC AGA GTA CATrGrG+G 3′.
ISPCR primer: 5′ AAG CAG TGG TAT CAA CGC AGAGT 
3′.
PC1 primer: 5′ AAT GAT ACG GCG ACC ACC GAG ATC 
TACAC 3′.
PC2 primer: 5′ CAA GCA GAA GAC GGC ATA CGA GAT 
3′.
In vitro transcription
The artificial DNA templates used in the transcription reac-
tions were generated by performing PCR using tailed prim-
ers that introduce a bacteriophage T7 promoter sequence 
at one end of the amplified DNA using the primers identi-
fied below. The DNA templates containing the CD36 gene 
were derived from microglia lysate extracted as described 
above. 200 µL PCR reactions were prepared to obtain suffi-
cient levels of product. 100 ng of T7-CD36 DNA was trans-
fected with 0.2 µL of Lipofectamine 2000 (Thermo Fisher 
11668030) for 6 h after which cells were washed with 37 °C 
media. Media was replaced and cells were kept for 5 days 
before stimulation with media changes at 24 and 36 h.
CD36 T7P forward primer: 5′ TAA TAC GAC TCA CTA 
TAG CCA CCA TGG GCT GTG ATC GGA ACT GTG 3′.
CD36 reverse primer: 5′ TTA TTT TCC ATT CTT GGA TTT 
GCA AGCAC 3′.
Macrophage phagocytosis assay and 
cytokine/chemokine assay
Mouse bone marrow-derived macrophages (BMDM) 
were plated in a 96-well black-bottom plate at a density of 
30,000 cells per well in complete BMDM medium. Cells 
were incubated for 24 h at 37 °C with 5%  CO2, after which 
the medium was changed to DMEM with 1% FBS. After 
1 h incubation, niacin (100 μM) was added to the cells, 
after which they were incubated for 12 h at 37 °C with 5% 
 CO2. The medium was then removed and pHrodo S. aureus 
BioParticles (pHrodo; Molecular Probes Invitrogen) was 
added at 100 μg/mL in 1× live cell imaging solution. To 
label live cells and nuclei, respectively, calcein AM (10 μM) 
and NucBlue Live ReadyProbes Reagent (two drops per mL; 
Thermo Fisher) were also added to the cells. The cells were 
then imaged on an ImageXpress Micro Cellular Imaging 
and Analysis System (Molecular Devices) over an hour. The 
percentage of calcein AM-positive and NucBlue-positive 
cells that were positive for pHrodo was quantified using 
MetaXpress software. Cytokine secretion was assessed using 
a tumor necrosis factor-α ELISA following the manufac-
turer’s instructions (Life Technologies).  Multiple cytokines 
and chemokines were examined using a multiplex analy-
sis (Eve Technologies).  For cytokine experiments, niacin 
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(100 μM) was added to cells followed by the addition of 
lipopolysaccharide (100 ng/mL) one hour later. Cells were 
then incubated for 24 hours after which conditioned medium 
was collected for analysis.
Experimental design and statistical analyses
For in vivo experiments, mice were randomly allocated to 
either the vehicle or niacin group. All microscopy analyses 
were performed blinded by an individual in the laboratory 
not involved in this particular study. Mice were housed in 
cages containing three to five animals in a specific pathogen-
free facility. Mice were housed at room temperature with 
a standard 12 h light/dark cycle with ad libitum access to 
water and standard diet. Mice were assessed once a day prior 
to the experiment, twice a day for the first 7 days following 
surgery, and daily thereafter. Sample size was determined 
by previous studies using the lysolecithin model with the 
corresponding outcome measure. All animal experiments 
had between three and nine mice per group. Saline vehicle or 
niacin (100 mg/kg IP) dissolved in saline was administered 
once a day at the same time every day for the duration of 
the experiment. No adverse events were observed following 
niacin treatment.
For experiments in which two groups were compared, 
a one- or two-tailed t test was performed for parametric 
data; for non-parametric data such as rank order analysis, 
the Mann–Whitney U test was used. For experiments in 
which there were more than two groups with one independ-
ent variable, a one-way ANOVA was conducted with either 
a Bonferroni post hoc test or a Dunnett’s post hoc test. For 
experiments in which there were more than two groups with 
two independent variables, a two-way ANOVA was utilized 
with a Bonferroni post hoc test.
Results
Primary microglia were isolated from young adult 
(6–8 weeks) mice to assess rates of engulfment of myelin 
debris and latex beads (Fig. 1a). After 4 h of exposure, there 
was more uptake of myelin compared to latex beads, and this 
progressively increased with time (Fig. 1b). As phagocytosis 
declines with age in macrophages [34, 39], we sought to cor-
roborate this finding in microglia from aged (> 15 month) 
mice. We observed a significant reduction in the uptake of 
myelin by microglia isolated from aged adult mice com-
pared to microglia isolated from neonate or young adult 
mice (Fig. 1c, d).
The results of preferential phagocytosis of myelin 
debris over inert beads suggest the involvement of specific 
receptor(s). To address this, we first determined the time lag 
between microglia activation and phagocytosis. Microglia 
were exposed to myelin debris and staining for intracellular 
iNOS demonstrate that 80% of cells were stimulated after 
2 h (Fig. 1e, f). We thus chose the 2 h time point for RNA 
sequencing and assessed the expression of selected signature 
genes associated with pro-inflammatory (Il1α, Tnf) or anti-
inflammatory (Arg1, Tgfb1) microglia activity. Myelin debris 
upregulated the pro-inflammatory Il1α and Tnf but not the 
anti-inflammatory genes (Fig. 1g). Overall, 1714 genes were 
differentially expressed with age and activation state in mye-
lin-stimulated young and aged microglia (Fig. 1h).
To determine the receptor(s) mediating phagocytosis of 
myelin debris, we examined the RNA sequencing dataset for 
genes differentially expressed with age and activation state 
(DAA). When comparing a scavenger receptor gene set to 
the DAA genes, we observed an overlap of 39.28% (11 out 
of 28 scavenger receptor genes; Fig. 1h). At 2 h and another 
12 h time point, we found significant alterations in the 
Fig. 1  Myelin debris activates microglia and myelin phagocytosis 
requires the scavenger receptor CD36. a Representative images of 
mouse microglia exposed to myelin debris and fluorescently conju-
gated latex beads (red) and stained for Iba1 (green) and MBP (red). 
b A greater percentage of microglia phagocytose myelin debris com-
pared to latex beads over time. c Representative images of neonate, 
young adult, and aged microglia exposed to myelin debris and stained 
for Iba1 (green) and MBP (red). d Neonate and young microglia 
phagocytose myelin debris with a significantly greater efficiency than 
aged microglia. e Representative images of mouse microglia exposed 
to myelin debris and stained for CD11b (green) and iNOS (red). f 
Myelin debris stimulates the expression of iNOS in CD11b+ micro-
glia. g  Log2 fold change of RNA expression of pro- and anti-
inflammatory genes from microglia activated with myelin debris 
for 2  h compared to naïve controls. h Venn diagram representation 
of the association of scavenger receptors in the set of differentially 
expressed genes (DAA) whose expression in microglia was regulated 
upon activation and that is affected due to aging. i, j Heat maps of 
expression levels of scavenger receptors (in DAA) in microglia iso-
lated from young and aging mice and activated for 2 (i) and 12 h (j). 
Euclidean distance matrix was used for hierarchical clustering. Dif-
ference in expression of scavenger receptors in microglia from aged 
mice was compared to microglia from young mice and the estimated 
 log2 fold change was plotted. k Representative images of mouse 
microglia exposed to myelin debris and treated with a CD36 recep-
tor antagonist (sulfo-N-succinimidyl oleate, SSO) and stained for 
Iba1 (red) and MBP (green). l SSO reduces microglia phagocytosis 
of myelin debris. m Representative images of young and aged micro-
glia exposed to myelin debris and treated with control, lipofectamine 
(Lipo), and overexpression of CD36 (CD36 OE) and stained for Iba1 
(red) and MBP (green). n Overexpression of CD36 significantly 
enhances myelin phagocytosis by young and aged mouse microglia 
as well as human microglia. Values are represented as mean with the 
standard error of the mean. Results were analyzed with a two-way 
repeated-measures ANOVA with a Bonferroni’s post hoc test (b, d), 
a one-way repeated-measures ANOVA with a Dunnett’s post hoc test 
(f, l), a Wald test and Benjamin–Hochberg p value adjustment (g, i, j), 
a two-sided Chi-square test with Yates’ correction (h), and a one-way 
ANOVA with a Bonferroni’s post hoc test (n each cell type analyzed 
individually). Values are indicative of triplicate cultures. For panels a, 
c, e, k, m, scale bars equal 50 μm. For panels b, d, f, l, n, *p < 0.05; 
**p < 0.01; ***p < 0.001; ****p < 0.0001. For panels g, i, j, *p < 0.05
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scavenger receptors Cd36, Stab1, Cd68, Cd14, Msr1, Cd44, 
Cxcl16, Clec7a, Scarb1, Olr1, and Cd163 between young 
and aged microglia (Fig. 1i, j). As CD36 was significantly 
downregulated in aged microglia and is a known receptor 
for the phagocytosis of oxidized phospholipids present in 
myelin debris [38], we focused on CD36. We found that 
a CD36 receptor antagonist (sulfo-N-succinimidyl oleate 
sodium, SSO) reduced phagocytosis by aged microglia in 
a concentration-dependent manner (Fig. 1k, l). Overexpres-
sion of CD36 through in vitro transcription resulted in a sig-
nificant increase in phagocytosis in microglia isolated from 
young and aged mice together with microglia isolated from 
human subjects (Fig. 1m, n).
To assess whether these findings translated to an in vivo 
model, the demyelinating toxin lysolecithin was injected 
into the ventrolateral funiculus of young (2–3 months) 
and middle-aged (9–12 months) mice. This typically pro-
duces in young mice an initial complete demyelination fol-
lowed by repopulation of OPCs by day 7 and remyelina-
tion by day 14–21 [19]. Analysis of lesion epicenter areas 
between young and middle-aged mice with the myelin 
stain, eriochrome cyanine, showed no statistically signifi-
cant differences on days 3, 7, or 21 (Supplementary Fig. 1, 
online resource). Staining for the pan-macrophage/micro-
glia marker Iba1 showed an initial low level of immuno-
reactivity in lesions of middle-aged mice (17% decrease 
compared to young mice) that eventually reached levels 
of young mice on day 21 (Fig. 2a, b). This delay was due 
to lower number of monocyte-derived macrophages rather 
than microglia in lesions of middle-aged animals when 
 CX3CR1CreER:Rosa26Tdt (Ai9) mice were used to discrimi-
nate Ai9+ microglia from Ai9− monocytes (24 h: 32% 
decrease; 72 h: 65% decrease) [36] (Fig. 2c–e). Phagocyto-
sis in lesions of middle-aged mice was examined with Oil 
Red O (ORO) to detect neutral lipids [24, 41]; phagocy-
tosed lipids concentrated in phagolysosomes have an intense, 
punctate appearance (Fig. 2f). Quantitation of punctate ORO 
showed significantly less ingested lipids on day 7 (42% 
decrease) in lesions of middle-age mice compared to lesions 
of young mice (Fig. 2g).
We previously screened a 1040 drug library for their 
capacity to enhance TNF-α production in lipopolysaccharide 
(LPS)-exposed adult human microglia and identified niacin 
(nicotinic acid, vitamin B3), meclocycline, bumetanide and 
orlistat with this effect [44]. Here, we used macrophages 
since they are a major phagocytic population in many 
neurological lesions [32], and can be purified easily from 
the bone marrow of young (2–3 months) and middle-aged 
(9–12 months) mice. All four compounds by themselves 
did not elicit an elevation of TNF-α (data not shown), but 
they significantly enhanced TNF-α levels in LPS-stimulated 
bone marrow-derived macrophages (BMDM) from both age 
groups (Fig. 3a, b). In considering which stimulator would 
be the best candidate for potential clinical use, we noted that 
meclocycline has an unfavorable safety profile, oral orlistat 
is not absorbed from the intestinal tract, and bumetanide has 
poor CNS penetrance (www.drugs .com). Niacin, however, 
is widely used and tolerated at high doses for prolonged 
periods and displays high bioavailability when taken orally 
to treat dyslipidemia [8, 25]. Moreover, the concentration we 
used of 100 μM is achievable in plasma in humans [6] and 
niacin is detected in the human brain after administration 
[16]. We assessed whether niacin is able to improve micro-
glial phagocytosis of myelin debris and found a significant 
enhancement of myelin debris uptake by both young and 
aged mouse microglia, as well as human microglia (Fig. 3c, 
d).
Niacin exerts its anti-lipolytic effects through the nia-
cin receptor, also known as GPR109A or the hydroxycar-
boxylic acid receptor 2 (Hcar2) [3, 25, 49]. To determine 
the involvement of this receptor, we isolated BMDM from 
wildtype and  Hcar2−/− mice. Multiplex Luminex analyses 
supported the TNF-α ELISA results and niacin induced ele-
vation of several cytokines and chemokines in LPS-exposed 
wildtype BMDM that was abrogated in  Hcar2−/− cells (Sup-
plementary Fig. 2a–h, online resource).
To determine whether niacin was binding to Hcar2 to 
mediate the increase in phagocytosis, we treated wildtype 
and  Hcar2−/− cells with niacin and only observed enhance-
ment in phagocytosis in wildtype cells (Fig. 3e). To address 
potential scavenger receptors mediating this increase in 
phagocytosis, we assessed transcripts from wildtype and 
 Hcar2−/− BMDM treated with niacin. We found that Cd68 
and Mertk were not affected by niacin treatment (Supple-
mentary Fig. 2i, j, online resource). However, niacin ele-
vated Cd36, which is downregulated in aged microglia and 
important for the phagocytosis of myelin debris (Fig. 3f).
Next, we tested whether the niacin-mediated enhance-
ment in phagocytosis was through CD36. Microglia were 
exposed to myelin and were treated with niacin in the pres-
ence of the CD36 receptor antagonist SSO. When niacin 
was added alone to microglia from young and aged mice, 
as well as from humans, a significant increase in phago-
cytosis was observed compared to control (Fig. 3g, h). In 
contrast, SSO ameliorated niacin-enhanced myelin phago-
cytosis (Fig. 3g, h). These results identify niacin as a novel 
stimulator of macrophage/microglia phagocytosis in culture 
that acts through Hcar2 to upregulate CD36 culminating in 
myelin engulfment.
Since Hcar2 expression was elevated in demyelinat-
ing lesions (young: 4361% increase; middle-aged: 1896% 
increase; Fig. 4b), we asked whether Hcar2 is necessary for 
remyelination to proceed efficiently. We induced lysoleci-
thin lesions in young wildtype and  Hcar2−/− mice and found 
no difference in the rate of OPC recruitment or remyelina-
tion, suggesting that Hcar2 is not necessary for spontaneous 
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remyelination (Supplementary Fig. 3a, b, online resource). 
We next addressed whether pharmacological stimulation 
of Hcar2 with the systemic administration of niacin would 
be sufficient to enhance remyelination in middle-aged mice 
(Fig. 4a). Wildtype or Cx3cr1GFP/+:Thy1YFP+ mice, demy-
elinated with lysolecithin, were treated with saline vehicle 
or niacin (100 mg/kg IP) once a day, with treatment starting 
24 h after lysolecithin (Fig. 4a). From the literature, this 
dose results in an initial spike in plasma concentration, after 
which the concentration is maintained at approximately 
240 µM from 2 to 6 h post-administration [51]. From 6 to 
9 h, the plasma concentration decreases to 120 µM, result-
ing in a concentration similar to the one achieved in humans 
taking 1 g of niacin [6]. In our experiments, live imaging 
Fig. 2  Middle-aged mice have decreased monocyte-derived mac-
rophage recruitment and impaired phagocytosis. a Representa-
tive images of lesions from young (2–3  month) and middle-aged 
(9–12  month) mice stained with the macrophage/microglia marker-
ionized calcium-binding adaptor molecule-1 (Iba1) at 3, 7, and 
21  days post-demyelination. b Lesions in middle-aged mice have 
significantly less Iba1 immunoreactivity than lesions in young mice 
at 7 days. c Representative images of lysolecithin lesions from young 
and middle-aged  CX3CR1CreER:Rosa26TdT (Ai9) mice stained with 
an antibody against CD45. d, e The number of microglia (Ai9+/
CD45+) within the lesion does not differ between young and middle-
aged mice. The number of peripheral leukocytes (CD45+), however, 
is significantly less in middle-aged mice at both time points. f Rep-
resentative bright field images of lesion epicenters from young and 
middle-aged mice stained with Oil Red O (ORO) at 3, 7, and 21 days 
post-demyelination. g Lesions in young mice have significantly more 
punctate ORO staining than lesions in middle-aged mice at 7  days 
post-demyelination. Values are represented as mean with the stand-
ard error of the mean. Results were analyzed with a two-way ANOVA 
with a Bonferroni’s post hoc test (b, d, e, g). For panels b, d, e, and 
g, between five and nine mice were analyzed per group. For panels a 
and f, scale bars equal 100 μm. For panel c, scale bars equal 50 μm. 
*p < 0.05; **p < 0.01
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revealed that the macrophages/microglia in niacin-treated 
middle-aged mice had higher mean surface area (59% 
increase) and volume (82% increase), and lower mean 
sphericity (that is, less ameboid; 4% decrease) (Fig. 4c–f), 
indicating that niacin enhanced their process extension and 
elevated their surveillance within lesions.
Since myelin debris is non-permissive for remyelination 
and needs to be removed for remyelination to occur [22, 37], 
we investigated the effect of niacin on myelin phagocytosis 
in vivo. Extending our tissue culture results (Fig. 3f), we 
found that niacin significantly increased the mean fluores-
cence intensity of CD36 expression by monocyte-derived 
macrophages and microglia within the lesion (Fig. 4g–j). 
To determine whether the elevated CD36 corresponded 
to lipid engulfment, we performed ex vivo live imaging 
experiments in which addition of the lipophilic dye, Nile 
Red, labels lipids that have been engulfed by Cx3cr1GFP/+ 
cells [39, 48]. We found that systemic niacin treatment 
significantly enhanced the amount of engulfed lipids within 
 CX3CR1GFP/+ macrophages/microglia on day 3 in middle-
aged mice (512% increase) (Fig. 4k, l). Niacin thus promotes 
the clearance of inhibitory myelin debris from lesions in 
middle-aged animals.
Other effects of niacin were examined. Ex vivo multipho-
ton live imaging of  CX3CR1GFP/+ mice at day 3 showed that 
niacin did not influence the motility of macrophages/micro-
glia within lesions in middle-aged animals (Supplementary 
Fig. 4, online resource). Niacin did not affect the inflamma-
tory profile of circulating blood monocytes after 3 or 7 days 
of daily treatment (Supplementary Fig. 5, online resource). 
In lesions on both day 3 and day 7 (Supplementary Fig. 4b 
and 6a,b, online resource), niacin did not alter the density 
of  CX3CR1GFP/+ or Iba1-stained macrophages/microglia, 
or changed the proportion of cells within the lesion that 
were microglia or infiltrating macrophages (Supplementary 
Fig. 6c,d, online resource). We conclude that niacin is not 
affecting circulating monocytes or the recruitment of mac-
rophages/microglia into lesions in middle-aged animals, but 
that it promotes the intralesional phagocytic clearance of 
inhibitory myelin debris.
With the removal of inhibitory myelin debris, daily 
niacin treatment increased the density of Olig2+ oli-
godendrocyte lineage cells (41% increase), including 
Olig2+PDGFRα+ OPCs (76% increase) (Fig.  5a–c) in 
demyelinated lesions in middle-aged mice. As niacin does 
not have a direct effect on OPCs in vitro (Supplementary 
Fig. 7, online resource), it seems likely that niacin is acting 
through the phagocytic removal of inhibitory myelin debris 
to enhance OPC recruitment within the lesion.
We examined whether systemic niacin treatment for 
the first 7 days after lysolecithin injection, when myelin 
breakdown and removal is largely occurring, was sufficient 
to promote remyelination on day 21 in middle-aged mice. 
This was first addressed by quantifying the percentage of 
MBP-positive rings within lesions, presumed to be newly 
formed myelin around axons. Niacin significantly increased 
the percentage of MBP-positive area within the lesion (138% 
increase) (Fig. 5d, e). To confirm that remyelination had 
occurred, we examined lesions by transmission electron 
microscopy (EM) (Fig. 5f). Lesions from mice treated with 
vehicle or niacin had the same density of axons (Supple-
mentary Fig. 8, online resource), suggesting that niacin was 
not neurotoxic despite its potential for elevating cytokines 
in culture (Fig. 3); the safety was corroborated by a similar 
expression of the pro-inflammatory IL-1β in lesions between 
groups (Supplementary Fig. 9, online resource).
The EM images with quantitation throughout the lesion 
core showed that the percentage of remyelinated axons was 
elevated by niacin (62% increase) (Fig. 5g). g ratio meas-
urements for myelin thickness (1 is complete demyelina-
tion) across all axonal calibers (Fig. 5h, i) provided an initial 
Fig. 3  Niacin is a novel stimulator of phagocytosis and acts through 
the niacin receptor (Hcar2) to upregulate CD36. a, b ELISA for 
TNF-α shows medications that increase TNF-α production in 
LPS (100 ng/mL)-stimulated condition in young (a) and middle-aged 
(from 9 to 12-month-old animals) (b) mouse BMDM. Note that with-
out LPS, the compounds did not elevate TNF-α (data not shown). c 
Representative images of young and aged (from > 15  month old) 
mouse microglia and human microglia exposed to myelin debris 
and treated with niacin (100  μM) and stained for Iba1 (red) and 
MBP (green). d Niacin (100 μM) by itself significantly increases the 
engulfment of MBP+ myelin debris within Iba1+ young and aged 
mouse microglia and human microglia. e Niacin (100 µM) by itself 
enhances phagocytosis and this is abrogated in  Hcar2−/− BMDM. f 
Niacin alone (100  µM) increases the expression of Cd36 mRNA in 
wildtype but not  Hcar2−/− BMDM. g Representative images of young 
and aged mouse microglia and human microglia exposed to myelin 
debris and treated with control, niacin (100  μM), sulfo-N-succinim-
idyl oleate (SSO), and niacin together with SSO. These cells were 
stained for Iba1 (red) and MBP (green). h The niacin-mediated 
increase in phagocytosis is abrogated in young and aged mouse 
microglia as well as human microglia treated with a CD36 antago-
nist (SSO). For panels a, b, values are represented as mean with the 
standard error of the mean of quadruplicate cultures. For panel d, 
values are represented as mean with the standard error of the mean 
of triplicate cultures. An independent experiment was performed for 
each cell type. For panel e, values are represented as mean with the 
standard error of the mean pooled from two independent experiments 
of quadruplicate cultures each. For panel f, values are represented 
as mean with the standard error of the mean pooled from two inde-
pendent experiments of triplicate cultures each. For panel h, values 
are represented as mean with the standard error of the mean of trip-
licate cultures. An independent experiment was performed for each 
cell type. For panels a, b, results were analyzed by one-way ANOVA 
with Dunnett post hoc test relative to the LPS group. For panel d, 
results were analyzed by one-tailed t test performed independently for 
each cell type. For panels e, f, results were normalized to the respec-
tive control mean value and then analyzed by two-way ANOVA with 
a Bonferroni’s post hoc test. For panel h, results were analyzed by 
one-way ANOVA with a Bonferroni’s post hoc test performed inde-
pendently for each cell type. For panels c, g, scale bars equal 50 μm. 
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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impression of lower g ratios (i.e., remyelinated) on larger 
axons in the niacin group (Fig. 5h), so we delineated small 
and large axons based on a 2.5 μm axonal caliber cutoff. 
The results show remyelination occurring similarly on small 
axons in both niacin and vehicle groups (Fig. 5j), but large 
axons were minimally remyelinated in middle-aged mice 
unless treated with niacin (Fig. 5k). These results demon-
strate that systemic treatment with niacin improves remyeli-
nation in the aging CNS, specifically in larger caliber axons 
that otherwise would not be remyelinated in aging after 
lysolecithin-induced demyelination.
Recently, it was shown that the ability for macrophages/
microglia to export phagocytosed cholesterol is important 
for preventing the formation of cholesterol crystals and 
lysosomal rupture within macrophages/microglia in demyeli-
nated lesions, and that this is reduced in aging [5]. The cho-
lesterol efflux is regulated by reverse cholesterol transport-
ers such as adenosine triphosphate-binding cassette (ABC) 
A1 (ABCA1) and G1 (ABCG1) on the plasma membrane 
[31], which are in turn controlled by liver × receptor alpha 
[13] that was previously shown to enhance remyelination 
in the aging CNS [5]. We did not find that niacin elevated 
Abca1 or Abcg1 in our study (Supplementary Fig. 10, online 
resource), thereby suggesting for the future that the combi-
nation of niacin promoting myelin engulfment together with 
a drug to stimulate cholesterol efflux could be even more 
effective for remyelination in aging animals.
Discussion
Several studies have found that the efficiency of remyelina-
tion is delayed in the aging CNS and that this deficiency is 
associated with an impaired macrophage/microglia response 
[14, 47, 53]. Macrophages/microglia are essential for remy-
elination as these cells phagocytose inhibitory myelin debris 
and provide growth factors for OPC maturation. With aging, 
macrophages/microglia display delayed lesion recruitment, 
decreased intralesional motility, as well as deficient phago-
cytosis, thereby contributing to a more inhibitory lesion 
microenvironment [5, 34, 39, 41, 53]. In this study, we con-
firmed these results using the lysolecithin model in young 
and middle-aged mice and examined whether remyelination 
could be enhanced by pharmacological stimulation of aging 
macrophages/microglia. We screened 1040 mostly generic 
medications from the NINDS Custom Collection II database 
for compounds that altered tumor necrosis factor-α secretion 
from activated human microglia [44]. From this screen, we 
discovered niacin, or vitamin B3, to be effective in stimulat-
ing tumor necrosis factor-α from human microglia. Further-
more, niacin was able to significantly enhance secretion of 
this cytokine from bone marrow-derived macrophages of 
young and older mice, in addition to enhancing phagocy-
tosis in young and aged (from > 15 months donors) mouse 
microglia as well as human microglia through the scavenger 
receptor CD36.
As niacin has an extensive clinical history when used in 
dyslipidemia and is well tolerated, we examined whether 
systemic niacin treatment would be effective in improving 
the deficient remyelination observed in middle-aged mice. 
Indeed, daily treatment with niacin enhanced myelin debris 
clearance, promoted OPC recruitment, as well as enhanced 
remyelination in lesions. Altogether, these results identify 
a novel clinically approved medication that is able to sig-
nificantly stimulate the innate immune system to enhance 
remyelination in the aging central nervous system.
Fig. 4  Niacin treatment of middle-aged mice alters macrophage/
microglia morphology and promotes myelin phagocytosis. a Sche-
matic depicting treatment paradigm with niacin. Middle-aged mice 
were injected with lysolecithin in either the dorsal or ventrolateral 
funiculi on day 0, after which niacin was administered intraperito-
neally (I.P.) once a day at a dose of 100  mg/kg from day 1 to day 
7. On day 3, lesioned dorsal spinal cord segments were isolated for 
ex  vivo multiphoton live imaging. On day 7, ventrolateral lesions 
were processed for immunofluorescence staining for oligodendro-
cyte progenitor cells (OPCs). On day 21, remyelination was assessed 
by immunofluorescence staining and electron microscopy of vent-
rolateral lesions. b RNA transcript of the niacin receptor is upregu-
lated in the lesion 3 days post-injury in both young and middle-aged 
mice. c Representative three-dimensional reconstructions of single 
 CX3CR1GFP/+ macrophage/microglia in 3  day lesions from middle-
aged mice administered with saline vehicle or niacin. d, e Niacin 
treatment significantly increases the mean surface area (d) and mean 
volume (e) of macrophages/microglia within the lesion. f Treatment 
with niacin significantly reduces the mean sphericity of macrophages/
microglia within the lesion. g Representative images depicting lesions 
immunostained for CD45 (green) and CD36 (white) at 3 days post-
demyelination from middle-aged demyelinated mice receiving either 
vehicle or niacin. h Representative images of lysolecithin lesions 
7 days post-demyelination from middle-aged  CX3CR1CreER:Rosa26Tdt 
(Ai9) mice treated with vehicle or niacin once a day for seven days. 
Both F4/80+/Ai9+ microglia (both magenta and green) as well as 
F4/80+/Ai9− peripheral macrophages (only magenta) express CD36 
(white). i Niacin treatment of middle-aged mice has no effect on the 
percentage of CD45+ cells expressing CD36 within lesions at 3 days 
post-demyelination; however, there was a significant increase in the 
mean fluorescence intensity (MFI) of CD36 on CD45+ cells within 
lesions (g, j). k Three-dimensional reconstruction of  CX3CR1GFP/+ 
macrophages/microglia containing Nile Red-positive phagosomes 
in lesions from middle-aged mice, with images acquired through 
ex vivo multiphoton live imaging 3 days post-demyelination. l Niacin 
enhances the amount of phagocytosed Nile Red-labeled lipid debris. 
Values are represented as mean with the standard error of the mean. 
Results were analyzed with a Wald test and Benjamin-Hochberg p 
value adjustment (b), two-tail student’s t test (d–f) or a one-tail stu-
dent’s t test (i, j, l). For panel b, each data point was generated from 
the analysis of RNA pooled from 5 mice. For panels d, e, f, between 
11 and 73 cells were quantified per mouse from 3 vehicle-treated 
mice and 4 niacin-treated mice. For panels i, j, l, each data point 
represents 1 mouse. For panels, d–f, i, j, l, *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001; n.s. not significant. For panel b, 
*p < 0.0001. Scale bars equal 5 μm (c), 20 μm (k), and 100 μm (g, h)
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Several approaches have been applied to accelerate remy-
elination in the young CNS [12]. These include directly 
enhancing oligodendrocyte differentiation and reducing 
the synthesis of inhibitory molecules such as chondroitin 
sulfate proteoglycans [9, 10, 20, 28, 33]. We have utilized 
the combination of amphotericin B and macrophage colony-
stimulating factor to promote the activity of young mac-
rophages [10]. These experiments have been conducted in 
young animals where the inflammatory response and OPC 
response are already very efficient. It is not clear whether 
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these approaches will be successful in the CNS with increas-
ing age due to the significant dysregulation in both the aging 
innate immune system as well as the OPC population. Fur-
thermore, it is not entirely clear what results in remyelina-
tion failure in MS. Myelin debris within lesions is only one 
aspect, but there are likely several other mechanisms that 
contribute to the remyelination block in MS. As lysolecithin 
lesions in aging rodents do eventually completely remyeli-
nate after 63 days, the lysolecithin model is not a very rep-
resentative model of remyelination failure in MS [51]. The 
establishment and validation of better representative animal 
models of progressive MS will be instrumental in dissect-
ing other pathological mechanisms underlying remyelination 
failure. In addition, as there is a strong correlation between 
increasing age with the onset of both primary and secondary 
progressive multiple sclerosis, it underscores the importance 
in establishing better animal models and discovering trans-
lational approaches to enhancing remyelination in the aging 
CNS [7, 15, 50].
Macrophages/microglia have been shown to have both 
beneficial and detrimental roles in remyelination [27]. As 
mentioned above, the beneficial roles include the clear-
ance of inhibitory myelin debris as well as the provision 
of important growth factors and metabolites. Despite these 
benefits, these cells have also been shown to be detrimental 
through the secretion of free radicals and reactive oxygen 
species in addition to the release of potentially harmful 
pro-inflammatory cytokines [40]. As we found that niacin 
was able to significantly upregulate the secretion of sev-
eral pro-inflammatory cytokines in vitro, including TNF-α 
which has been shown to be toxic in its soluble form through 
TNFR1 on oligodendrocytes [4], we were concerned that 
niacin treatment in middle-aged mice may exacerbate neuro-
toxicity. We do not think that this is the case, however, as we 
found no difference in axonal density with niacin treatment. 
Furthermore, niacin treatment of mice induced with experi-
mental autoimmune encephalomyelitis, an inflammatory 
model of MS, improved disease score and minimized the 
degree of inflammatory infiltrates in the CNS [52]. As pro-
inflammatory macrophages/microglia have been previously 
shown to be important for remyelination [1, 26, 30], we may 
be harnessing the beneficial aspects of these cells without 
causing significant cell death or neurotoxicity. It is also reas-
suring that we did not find elevation of pro-inflammatory 
monocytes in the circulation of niacin-treated mice, sug-
gesting its safety in patients with inflammatory demyelinat-
ing diseases including MS. Altogether, these results further 
emphasize the potential clinical utility of using niacin for 
remyelination.
In conclusion, we provide a clinically relevant direction 
to reverse the deficient macrophage/microglia response in 
middle-aged mice that contributes to deficient remyelinat-
ing activity. We have identified niacin as a novel clinically 
approved medication that enhances macrophage/microglia 
phagocytosis of inhibitory debris, resulting in increased 
OPC recruitment and ultimately remyelination in the aging 
CNS. It is interesting to note that niacin treatment promoted 
the remyelination of large caliber axons, which would sug-
gest that CNS regions that have predominantly small axons 
such as the corpus callosum may not be significantly affected 
by the pro-remyelinating activity of niacin. Alternately, our 
results suggest that small caliber axons are efficient at remy-
elinating spontaneously, but that large caliber axons require 
the intermediary of a stimulator such as niacin. Examining 
the effect of niacin in an inflammatory model of MS where 
newly generated oligodendrocytes can be fate mapped in 
different CNS regions will be an experimental approach 
to address whether this is indeed the case [29]. Finally, as 
phagocytosis is increasingly thought to be important in 
other conditions such as the clearance of Aβ in Alzheimer’s 
disease or α-synuclein in Parkinson’s disease, we would 
propose that niacin is a promising candidate for translation 
across many disorders where stimulating macrophages/
microglia is a desired outcome.
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